Cardiovascular Devices · Neurotech & Neuromodulation
Boston Scientific revenue, results and funding
Boston Scientific filed revenue of $20.1B for 2025.
Data updated Nov 20, 2026 · Back to the company report
$20.1BRevenue, 2025
$2.9BNet income, 2025
BSXNew York Stock Exchange
$7MPublic grants
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_DIVIDENDS | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $20.1B | $2.9B | $43.7B | $561M | $493M | – | – | $876M | $299M | $2.1B | $3.6B | $2B | – | $1.6B |
| 2024 | $16.7B | $1.8B | $39.4B | $656M | $436M | $0 | – | $790M | $266M | $1.6B | $2.6B | $414M | – | $4.6B |
| 2023 | $14.2B | $1.6B | $35.1B | $512M | $393M | $28M | – | $711M | $233M | $1.4B | $2.3B | $865M | – | $1.8B |
| 2022 | $12.7B | $698M | $32.5B | $662M | $443M | $55M | $0 | $588M | $220M | $1.3B | $1.6B | $928M | – | $1.5B |
| 2021 | $11.9B | $1B | $32.2B | $302M | $36M | $55M | $0 | $554M | $194M | $1.2B | $1.2B | $1.9B | – | $2.3B |
| 2020 | $9.9B | −$82M | $30.8B | $207M | $2M | $28M | $535M | $376M | $170M | $1.1B | −$80M | $1.7B | – | $3M |
| 2019 | $10.7B | $4.7B | $30.6B | $242M | −$4B | $0 | $0 | $461M | $157M | $1.2B | $1.5B | $217M | – | $4.4B |
| 2018 | $9.8B | $1.7B | $21B | $1B | −$249M | $0 | $0 | $316M | $140M | $1.1B | $1.5B | $146M | – | $1.4B |
| 2017 | $9B | $104M | $19B | $42M | $828M | – | – | $319M | $127M | $997M | $1.3B | $188M | $3.8B | $560M |
| 2016 | $9.1B | $347M | $18.1B | $94M | −$170M | – | $0 | $376M | $116M | $920M | $447M | $196M | $5.4B | $408M |
| 2015 | $8.1B | −$239M | $18.1B | $80M | −$411M | – | $0 | $247M | $107M | $876M | −$283M | $319M | $5.7B | $1.7B |
| 2014 | $7.5B | −$119M | $17B | $74M | −$390M | – | $125M | $259M | $103M | $817M | −$301M | $587M | $4.2B | $486M |
| 2013 | $7.1B | −$121M | $16.6B | $67M | −$102M | – | $500M | $245M | $105M | $861M | $120M | $217M | $4.2B | $274M |
| 2012 | $7.2B | −$4.1B | $17.2B | $97M | −$39M | – | $600M | $226M | $108M | $886M | −$3.9B | $207M | $4.2B | $366M |
| 2011 | $7.6B | $441M | $21.3B | $138M | $201M | – | $492M | $304M | $128M | $895M | $904M | $267M | $4.2B | $370M |
Sources: SEC
Rounds and grants
| Year | Round | Amount |
|---|---|---|
| 2023 | Grant | $179k |
| 2023 | Grant | $67k |
| 2022 | Grant | $949k |
| 2021 | Grant | $1.9M |
| 2020 | Grant | $509k |
| 2020 | Grant | $270k |
| 2020 | Grant | $64k |
| 2019 | Grant | $395k |
| 2018 | Grant | $128k |
| 2017 | Grant | $870k |
| 2017 | Grant | $330k |
| 2016 | Grant | $550k |
| 2015 | Grant | $772k |
Sources: funding announcements, SEC filings, grant registers
How to cite
Boston Scientific, Financials. Alion, Nov 20, 2026. https://alion.io/company/bostonscientific-com/financials
